Holding(s) in Company

RNS Number:2816Q
Cambridge Antibody Tech Group PLC
19 August 2005

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES



1. Name of company


Cambridge Antibody Technology Group plc


2. Name of shareholder having a major interest


Wellington Management Company LLP


3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18


Non beneficial


4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them


Investment Advisor. Names of separate accounts not disclosed. The shares are
registered in the name of the Accounts of the Accounts Custodians or nominees
according to their respective holdings.


5. Number of shares / amount of stock acquired


not disclosed


6. Percentage of issued class


N/A


7. Number of shares / amount of stock disposed


not disclosed


8. Percentage of issued class


N/A


9. Class of security


ordinary 10 pence shares


10. Date of transaction


not disclosed



11. Date company informed


18 August 2005


12. Total holding following this notification


4,118,994


13. Total percentage holding of issued class following this notification


7.98%


14. Any additional information


The Accounts do not act as a group nor do they act in concert with respect to
the interests in shares.


15. Name of contact and telephone number for queries


Justin Hoskins 01223 898589


16. Name and signature of authorised company official responsible for making
this notification


Justin Hoskins Company Secretary


Date of notification


19 August 2005



The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

HOLEANPNFDXSEEE